[CUR] Neuralstem, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.31 Change: 0.02 (8.21%)
Ext. hours: Change: 0 (0%)

chart CUR

Refresh chart

Strongest Trends Summary For CUR

CUR is in the medium-term down -32% below S&P in 3 months and down -86% below S&P in 7 months. In the long-term down -97% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds. The company?s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical program products include NSI?566, which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, and Phase I clinical trials for chronic spinal cord injury. The company?s clinical development products also comprise NSI?566 that is in Phase I/II clinical trials for motor deficits due to ischemic stroke in China; and NSI?189 that is in Phase Ib for the treatment of major depressive disorders. Neuralstem, Inc. was founded in 1996 and is headquartered in Rockville, Maryland.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -40% Sales Growth - Q/Q-40% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-70.66% ROE-112.4% ROI-82.24%
Current Ratio6.72 Quick Ratio Long Term Debt/Equity0.28 Debt Ratio0.22
Gross Margin Operating Margin-93733.3% Net Profit Margin-120900% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5.89 M Cash From Investing Activities-100 K Cash From Operating Activities-4.72 M Gross Profit
Net Profit-5.05 M Operating Profit-4.61 M Total Assets30.8 M Total Current Assets29.15 M
Total Current Liabilities4.34 M Total Debt8.88 M Total Liabilities11.44 M Total Revenue
Technical Data
High 52 week13.09 Low 52 week0.3 Last close1.35 Last change3.85%
RSI33.73 Average true range0.15 Beta0.71 Volume457.73 K
Simple moving average 20 days-10.15% Simple moving average 50 days-20.81% Simple moving average 200 days-73.05%
Performance Data
Performance Week5.47% Performance Month-22.86% Performance Quart-83.54% Performance Half-84.66%
Performance Year33.74% Performance Year-to-date331.17% Volatility daily4.88% Volatility weekly10.91%
Volatility monthly22.35% Volatility yearly77.42% Relative Volume618.32% Average Volume119.7 K
New High New Low

News

2019-10-31 11:00:00 | Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA

2019-10-30 07:00:00 | Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases

2019-10-29 14:28:48 | Local biopharma rebrands as part of commercialization strategy

2019-10-29 01:17:00 | Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit

2019-10-28 23:24:00 | Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit

2019-10-28 09:00:00 | Neuralstem Becomes Seneca Biopharma

2019-10-03 09:31:00 | Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636c4

2019-09-24 13:56:56 | Neuralstem regained Nasdaq compliance. Now it’s pushing forward with clinical trials.

2019-09-24 07:30:00 | Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

2019-08-14 07:30:00 | Neuralstem Reports Second Quarter 2019 Fiscal Results

2019-08-07 11:27:59 | Germantown biopharma regains compliance with Nasdaq

2019-08-07 07:30:00 | Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing

2019-07-31 07:30:00 | Neuralstem Closes $7.5 Million Underwritten Public Offering

2019-07-25 22:40:00 | Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering

2019-07-18 07:30:00 | Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors

2019-07-16 07:30:00 | Neuralstem Announces a 1-for-20 Reverse Stock Split

2019-07-09 13:39:47 | Germantown stem cell therapy company proposes $7M offering amid delisting threat

2019-07-01 16:30:00 | Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

2019-06-03 14:55:22 | Germantown biopharma stock on the brink of delisting

2019-05-16 07:07:00 | Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells

2019-05-14 16:30:00 | Neuralstem Reports First Quarter 2019 Fiscal Results

2019-05-06 07:00:00 | Neuralstem Appoints David J. Mazzo, Ph.D., to Board of Directors

2019-04-29 10:02:41 | Some Neuralstem NASDAQ:CUR Shareholders Have Copped A 99% Share Price Wipe Out

2019-03-22 16:30:00 | Neuralstem Reports Year End 2018 Fiscal Results

2019-02-07 07:00:00 | Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort

2018-12-31 16:08:01 | Penny Stocks to Buy Using Technical Analysis for January 2019

2018-12-18 07:00:00 | Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board

2018-12-04 05:00:00 | Germantown biotech faces stock delisting threat

2018-11-27 10:22:20 | How Financially Strong Is Neuralstem Inc NASDAQ:CUR?

2018-11-19 07:55:00 | Market Trends Toward New Normal in Neuralstem, Industrial Services of America, Gulf Resources, Natural Alternatives International, Lifevantage, and Lonestar Resources US — Emerging Consolidated Expectations, Analyst Ratings

2018-11-14 17:00:00 | Neuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update

2018-10-26 09:00:00 | Neuralstem Announces $2.1 Million Registered Direct Offering

2018-10-25 07:00:00 | Neuralstem Announces Publication of a Study Showing Benefits of Neural Stem Cell NSC Transplantation in a Mouse Model of Alzheimer’s Disease 

2018-09-18 11:20:37 | Should You Have Neuralstem Inc’s NASDAQ:CUR In Your Portfolio?

2018-08-15 10:24:24 | Neuralstem Provides Business Update and Reports Second Quarter 2018 Fiscal Results

2018-08-09 07:00:00 | Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

2018-08-07 14:41:23 | Germantown biopharma Neuralstem appoints interim CEO

2018-08-06 07:00:00 | Neuralstem Appoints Jim Scully as Interim Chief Executive Officer

2018-08-01 09:05:46 | CORRECTING and REPLACING -- Neuralstem, Inc.

2018-08-01 09:01:56 | Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

2018-07-31 18:14:42 | Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke

2018-07-23 11:50:21 | Neuralstem Announces Presentation of Preclinical Data Demonstrating Neurogenic Compound NSI-189 Improves Cognition and Anxiety in a Mouse Model of Alzheimer’s Disease

2018-06-12 08:00:00 | Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors

2018-06-11 07:00:00 | Neuralstem Awarded Phase I SBIR Contract to Support Research into Neural Stem Cell Therapy for Severe Traumatic Brain Injury

2018-06-04 07:00:00 | Neuralstem’s NSI-566 stem cell therapy confers neurological improvement in spinal cord injury patients with complete paraplegia

2018-05-29 07:00:00 | Neuralstem to Participate at the BIO 2018 International Convention

2018-05-15 07:00:00 | Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results

2018-05-03 07:00:00 | Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology

2018-04-18 07:00:00 | Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners Foundation

2018-04-11 08:30:00 | Today’s Research Reports on Trending Tickers: Neuralstem and Immunomedics